BACKGROUND & AIMS: Survival of patients with hepatocellular carcinoma (HCC) is determined by hepatic function and tumour extent. Recently, a new Model to Estimate Survival in Ambulatory HCC patients (MESIAH) was proposed to predict overall survival in ambulatory HCC patients. This study aimed to evaluate the prognostic performance of the MESIAH score in an independent cohort of HCC patients. METHODS: A cohort of 1969 patients newly diagnosed with HCC at the National Cancer Center, Korea between January 2004 and December 2009 was used for validation of the MESIAH score. The model's performance was assessed using C-statistics, the likelihood ratio (LR) χ2 value and Akaike information criterion (AIC). RESULTS: Patients in the cohort had a median age of 56 years and 83.2% were men. Hepatitis B virus infection was present in 74.6 and 81.6% had a Child-Pugh class A. The median overall survival was 21.4 months. The MESIAH score had a higher degree of discrimination, with a C-statistic of 0.792 [95% confidence interval (CI), 0.782-0.803], when compared with the Barcelona Clinic Liver Cancer (BCLC) staging system [0.665 (95% CI, 0.653-0.678), P<0.001]. The LR χ2 value and the AIC of MESIAH were also better than those of BCLC, Cancer of the Liver Italian Program, Japan Integrated Scoring and Tokyo score. The observed survival in the cohort closely matched that predicted by the MESIAH score. CONCLUSIONS: The new prognostication model MESIAH accurately estimated the overall survival of Korean HCC patients and may be useful in future research as well as individual patient care.
BACKGROUND & AIMS: Survival of patients with hepatocellular carcinoma (HCC) is determined by hepatic function and tumour extent. Recently, a new Model to Estimate Survival in Ambulatory HCCpatients (MESIAH) was proposed to predict overall survival in ambulatory HCCpatients. This study aimed to evaluate the prognostic performance of the MESIAH score in an independent cohort of HCCpatients. METHODS: A cohort of 1969 patients newly diagnosed with HCC at the National Cancer Center, Korea between January 2004 and December 2009 was used for validation of the MESIAH score. The model's performance was assessed using C-statistics, the likelihood ratio (LR) χ2 value and Akaike information criterion (AIC). RESULTS:Patients in the cohort had a median age of 56 years and 83.2% were men. Hepatitis B virus infection was present in 74.6 and 81.6% had a Child-Pugh class A. The median overall survival was 21.4 months. The MESIAH score had a higher degree of discrimination, with a C-statistic of 0.792 [95% confidence interval (CI), 0.782-0.803], when compared with the Barcelona Clinic Liver Cancer (BCLC) staging system [0.665 (95% CI, 0.653-0.678), P<0.001]. The LR χ2 value and the AIC of MESIAH were also better than those of BCLC, Cancer of the Liver Italian Program, Japan Integrated Scoring and Tokyo score. The observed survival in the cohort closely matched that predicted by the MESIAH score. CONCLUSIONS: The new prognostication model MESIAH accurately estimated the overall survival of Korean HCCpatients and may be useful in future research as well as individual patient care.
Authors: Swee H Teh; David M Nagorney; Susanna R Stevens; Kenneth P Offord; Terry M Therneau; David J Plevak; Jayant A Talwalkar; W Ray Kim; Patrick S Kamath Journal: Gastroenterology Date: 2007-01-25 Impact factor: 22.682
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Rebecca A Schroeder; Carlos E Marroquin; Barbara Phillips Bute; Shukri Khuri; William G Henderson; Paul C Kuo Journal: Ann Surg Date: 2006-03 Impact factor: 12.969
Authors: Byung-Ho Nam; Joong-Won Park; Sook-Hyang Jeong; Sang Soo Lee; Ami Yu; Bo Hyun Kim; W Ray Kim Journal: PLoS One Date: 2015-10-21 Impact factor: 3.240
Authors: Jeong-Ju Yoo; Su Jong Yu; Bora Lee; Eun Ju Cho; Jeong-Hoon Lee; Sang Gyune Kim; Yoon Jun Kim; Young Seok Kim; Jung-Hwan Yoon Journal: Gut Liver Date: 2020-05-15 Impact factor: 4.519
Authors: Fabio Farinati; Alessandro Vitale; Gaya Spolverato; Timothy M Pawlik; Teh-la Huo; Yun-Hsuan Lee; Anna Chiara Frigo; Anna Giacomin; Edoardo G Giannini; Francesca Ciccarese; Fabio Piscaglia; Gian Lodovico Rapaccini; Mariella Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Rodolfo Sacco; Filomena Morisco; Elisabetta Biasini; Francesco Giuseppe Foschi; Antonio Gasbarrini; Gianluca Svegliati Baroni; Roberto Virdone; Alberto Masotto; Franco Trevisani; Umberto Cillo Journal: PLoS Med Date: 2016-04-26 Impact factor: 11.069